Unlock instant, AI-driven research and patent intelligence for your innovation.

Thiophene and benzothiophene hydroxamic acid derivatives

A phenyl and compound technology, applied in the field of hydroxamic acid derivatives with benzothiophene or thiophene skeleton, can solve the problems of excessive proliferation of leukemia cell lines, inability to complete differentiation of tumor cells, etc.

Inactive Publication Date: 2007-01-24
ATON PHARMA
View PDF13 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Neoplastic cells fail to complete differentiation in this manner, resulting in hyperproliferative leukemia cell lines

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Thiophene and benzothiophene hydroxamic acid derivatives
  • Thiophene and benzothiophene hydroxamic acid derivatives
  • Thiophene and benzothiophene hydroxamic acid derivatives

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 2

[0948] Example 2 - Inhibitory effect of novel compounds on HDAC

[0949] HDAC1-Flag test:

[0950] The ability of novel compounds to inhibit histone deacetylase, isoform 1 (HDAC1) was determined using an in vitro deacetylation assay. The enzyme source used for this test was epitope-tagged human HDAC1 obtained from immunopurified cells stably expressing mammalian cells. The substrate consisted of a commercial product containing acetylated lysine side chains (BIOMOL Research Laboratories, Inc., Plymouth Meeting, PA). After deacetylation of the substrate by incubation with purified HDAC1 complex, a fluorophore commensurate with the level of deacetylation is generated. The concentration of the substrate used in the enzyme preparation was Km, and the deacetylation test was performed with increasing concentrations of novel compounds to semiquantitatively determine the concentration of the compound required to inhibit 50% of the deacetylation reaction (IC50).

[0951] result:

[...

Embodiment 3

[0984] Example 3 - HDAC Inhibition in Cell Lines

[0985] MTS test

[0986] The novel compounds of the present invention were tested for their ability to inhibit the proliferation of the murine erythroleukemic cell line SC9.

[0987] MTS assay, also known as Cell Titer 96 Aqueous One Solution Cell Proliferation Assay (96-well cell titer plate single aqueous solution cell proliferation assay), is a colorimetric method for determining the number of living cells in proliferation, cytotoxicity or chemical sensitivity analysis. MTS reagent contains a novel tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H - tetrazolium, inner salt] and electron coupling reagent (phenazine ethyl sulfate; PES). Murine erythroleukemia cells (SC-9) were incubated with vehicle or increasing concentrations of compounds for 48 hours. Cell proliferation was quantified by adding a small amount of MTS reagent directly to the culture wells, incubating for 1-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a novel hydroxamic acid derivative with benzothiophene or thiophene skeleton. The hydroxamic acid compounds are useful in the treatment of cancer. The hydroxamic acid compound can also inhibit histone deacetylase, and is suitable for selectively inducing terminal differentiation, cell growth arrest and / or apoptosis of neoplastic cells to inhibit the proliferation of these cells. Accordingly, the compounds of the present invention are useful in the treatment of subjects having tumors characterized by neoplastic cell proliferation. The compounds of the present invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and / or treatment of central nervous system diseases (CNS), such as neurodegeneration disease. The present invention also provides pharmaceutical compositions comprising said hydroxamic acid derivatives and safe dosage regimens of these pharmaceutical compositions which are easy to follow and which produce therapeutically effective amounts of said hydroxamic acid derivatives in vivo.

Description

field of invention [0001] The invention relates to a novel hydroxamic acid derivative with benzothiophene or thiophene skeleton. The hydroxamic acid compounds are useful in the treatment of cancer. The hydroxamic acid compound can also inhibit histone deacetylase and is suitable for selectively inducing terminal differentiation, cell growth arrest and / or apoptosis of neoplastic cells, thereby inhibiting the proliferation of such cells. Accordingly, the compounds of the present invention are useful in the treatment of patients with tumors characterized by neoplastic cell proliferation. The compounds of the present invention are also useful for the prevention and treatment of TRX (thioredoxin)-mediated diseases, such as autoimmune diseases, allergic and inflammatory diseases, and for the prevention and / or treatment of central nervous system (CNS ) diseases, such as neurodegenerative diseases. Background of the invention [0002] Compounds with hydroxami...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/381C07D333/36C07D333/38C07D333/72
Inventor T·A·米勒D·J·韦特S·贝尔韦德雷
Owner ATON PHARMA